Akebia Therapeutics, Inc. revised revenue guidance for the year 2023. The company slightly lowered Auryxia net product revenue guidance to $170 million - $175 million for 2023 from $175 million - $180 million due to an unfavorable impact from market dynamics, volume and payor mix.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | 0.00% | -10.85% | -7.26% |
May. 09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.26% | 241M | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.67% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023